Drug intelligence / Profile preview

bupivacaine + lidocaine + epinephrine + morphine

Development stage
Phase 3
Lead developer
Assiut University
Modality
Small Molecules
Administration
Intraperitoneal, Implant
01

Overview

This combination drug preparation is an analgesic mixture investigated for the management of postoperative pain, specifically following laparoscopic cholecystectomy. It consists of two local anesthetics, bupivacaine and lidocaine, which provide rapid and prolonged blockade of nerve conduction; epinephrine, a vasoconstrictor added to reduce systemic absorption and extend the duration of the local anesthetic effect; and morphine, an opioid analgesic that provides regional pain relief. In clinical study contexts, this mixture is often soaked into an absorbable hemostatic material, such as Surgicel, which acts as a reservoir for the sustained local release of the medications at the surgical site (e.g., the gallbladder bed or port sites). The preparation was developed and studied by researchers at Assiut University.

Other names
local anesthetic + epinephrine + morphinebupivacaine + lidocaine + epinephrine + morphine + Surgicel
02

Targets

ADRA1A (α1A)ADRA2A (α2A)ADRB2 (β2)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)ADRA1 (Alpha-1 adrenergic receptor family)ADRB1 (β1)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on bupivacaine + lidocaine + epinephrine + morphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupivacaine + lidocaine + epinephrine + morphine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call